Austin, TX - February 11, 2025

Akexis is pleased to announce that internationally renowned lung cancer expert Dr. Philip Bonomi has joined the company as Chief Medical Officer (CMO). With over 47 years of clinical experience and a distinguished career at Rush University Medical Center, Dr. Bonomi brings unparalleled expertise to Akexis as the company works to transform the standard of care for late-stage cancer patients through innovative therapies addressing cancer cachexia and other critical treatment gaps.

During his tenure at Rush, Dr. Bonomi was a pioneering leader in oncology, contributing to the development of numerous cancer-fighting drugs and therapy combinations, particularly in the treatment of lung cancer and mesothelioma. He has authored or co-authored 270  publications with his most recent papers being devoted to cancer cachexia.  Having received the International Association for the Study of Lung Cancer’s Care Team Award and Lungevity’s Face of Hope Award, he is recognized globally for his leadership in clinical research and compassionate care for cancer patients

In his new role as CMO, Dr. Bonomi will oversee the clinical strategy and development of Akexis's therapeutic pipeline. His focus will be on advancing treatments designed to address the underlying causes of cancer cachexia, a debilitating condition that affects many late-stage cancer patients.

"I’m excited to join Akexis and contribute to its mission of developing transformative cancer therapies," said Dr. Bonomi. "Cancer cachexia is a complex and often overlooked challenge in oncology care. Akexis is uniquely positioned to address this critical issue and improve the lives of patients."

Dr. Lingbing Zhang, Founder and CEO of Akexis, shared his enthusiasm about Dr. Bonomi’s appointment: "Having someone of Dr. Bonomi's experience and dedication on our leadership team is a tremendous honor. His deep clinical expertise and passion for patient care will be invaluable as we continue to push boundaries in cancer therapeutics and redefine what's possible for late-stage cancer patients."

Akexis remains committed to advancing innovative cancer treatments that address significant unmet medical needs, including therapies targeting immune dysfunction in cancer cachexia. Dr. Bonomi’s leadership will play a vital role in accelerating the company’s efforts to bring these transformative therapies to market.

For more information on Akexis and its research initiatives, visit www.akexis.com.

About Akexis:
Akexis is a biotechnology company dedicated to developing transformative cancer therapeutics. Led by a team of seasoned scientists, clinicians, and innovators, Akexis is committed to advancing solutions that address the highly unmet needs of late-stage cancer patients. Akexis’s mission is to save lives and conquer late-stage cancer through groundbreaking science and the development of first-in-class therapies where no options currently exist. Our vision is to revolutionize late-stage cancer by pushing boundaries and transforming it from a terminal disease to a manageable and curable condition. Through innovative approaches and tailored treatments, we aim to empower patients with new possibilities for long-term remission and improved quality of life. For inquiries on partnering and investing please contact Suzanne Kennedy at skennedy@akexis.com.